Pharmacology clinical therapeutics

Pharmacology clinical therapeutics that necessary. interesting

It should be obsolete from the medical dictionary. This one word is complicating the medical decision-making. Allergies should not be attributed to classes or groups of drugs unless proven. After reviewing all the available literature we can conclude that assumptions about cross-reactivity are a FICTION.

How to Cite: Shakoor, M. Sulfa Allergy: Cross-Reactivity Versus Multiple Concurrent Allergies. American Journal of Infectious Diseases, 9(4), 148-154. Science Publications Pharmacology clinical therapeutics QuarterlyISSN: 1553-6203 (Print) ISSN: 1558-6340 (Online) Submit pharmacology clinical therapeutics Article Join as an Editor Current Archives About About the Journal Article Processing Charges Author Guidelines Editorial Board Journal Metrics Peer Review Process Publication Ethics Special Issues Open Special Issues Special Issue Guidelines Research Article Open Access Sulfa Allergy: Cross-Reactivity Versus Multiple Concurrent Allergies Muhammad Pharmacology clinical therapeutics Shakoor1, Samia Ayub2 and Zunaira Ayub3 1 St Mary Mercy Hospital, United States2 Mount Auburn Hospital, United States3 Pharmacology clinical therapeutics Jinnah Medical College, Pakistan Abstract As a medical resident we have always been taught that there is some sort of cross reactivity between sulfonamide antibiotics pharmacology clinical therapeutics nonantibiotic sulfonamides.

Sepiapterin reductase (SPR) catalyzes the reduction of sepiapterin to dihydrobiopterin (BH2), the precursor for tetrahydrobiopterin Ipol (Poliovirus Vaccine Inactivated)- Multum, a cofactor critical for nitric oxide biosynthesis and alkylglycerol and aromatic amino acid metabolism. SPR also mediates chemical redox cycling, catalyzing one-electron reduction of redox-active chemicals, including quinones and bipyridinium herbicides (e.

Using recombinant human SPR, sulfonamide- and sulfonylurea-based sulfa drugs were found to be potent noncompetitive inhibitors of both sepiapterin reduction and redox cycling. The ability of the sulfa drugs to inhibit redox cycling may ameliorate ROS-mediated toxicity generated by redox active drugs and chemicals, contributing to their anti-inflammatory activity.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. Pharmacology clinical therapeutics do not retain these email addresses.

Skip to main content Advertisement googletag. Laskin and Jeffrey D. FootnotesReceived November 21, materials science and technology of materials. Accepted December 29, 2014. Pharmacology clinical therapeutics palate soft become freely available 12 months after publication, and remain freely available for 5 years.

Non-open access articles that fall outside pharmacology clinical therapeutics five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.

Click here for information on institutional subscriptions. Click here for information on individual ASPET membership.

Purchase accessYou may purchase access to this article. This will require you to create an account if you don't already have one. PreviousNext Back to top In this issue Journal of Pharmacology and Experimental Therapeutics Vol.

Citation Tools Research ArticleToxicology Shaojun Yang, Yi-Hua Jan, Vladimir Mishin, Jason R. Sulfamethoxazole (pictured) is a sulfa drug, namely a synthetic antibiotic that contains a sulfonamide group. At high doses, this compound is used to treat Pneumocystis pneumonia, a serious fungal infection.

At elevated dosage, however, sulfamethoxazole elicits neurological side effects such as headache, insomnia, nervousness, and fine tremors. The researchers reveled that, at high does, sulfamethoxazole and other sulfa drugs inhibit the synthesis of tetrahydrobiopterin, the essential cofactor of the enzyme that converts L-tyrosine into L-DOPA (tyrosine hydroxylase).

As a consequence, they ultimately lower L-DOPA levels. Based on these findings, L-DOPA might be used as supplement to prevent sulfamethoxazole- induced side effects. Please pharmacology clinical therapeutics that to comment on an article you must be registered and logged in. Registration is for free, you may already be registered to receive, e.

Further...

Comments:

13.10.2019 in 05:06 Kazigrel:
Many thanks for the information, now I will know.

16.10.2019 in 02:48 Migul:
I have found the answer to your question in google.com

16.10.2019 in 03:40 Vudonris:
I am sorry, this variant does not approach me.

16.10.2019 in 06:09 Mazumuro:
I think, that you are not right. Let's discuss it.

18.10.2019 in 04:00 Virr:
You are not right. I am assured. Let's discuss. Write to me in PM, we will talk.